Trimethoprim: A Comprehensive Study on Mechanism, Applications, and Resistance > 공지사항

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction

Trimethoprim (TMP) is a synthetic antibacterial agent belonging to the class of diaminopyrimidines. First introduced into clinical practice in the late 1960s, it has since become a cornerstone in the treatment of a wide range of bacterial infections, particularly those affecting the urinary and respiratory tracts. Its primary clinical significance is often in combination with sulfamethoxazole (SMX) as co-trimoxazole, a potent synergistic formulation. This report provides a detailed examination of trimethoprim, covering its chemical properties, mechanism of action, pharmacokinetics, spectrum of activity, clinical applications, adverse effects, and the growing challenge of antimicrobial resistance.

Chemical Structure and Properties

Trimethoprim is chemically described as 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine. It is a weak base with a pKa of approximately 7.3. The molecule's structure is pivotal to its function: the diaminopyrimidine moiety mimics dihydrofolate, allowing it to bind competitively to a bacterial enzyme, while the trimethoxybenzyl group enhances its lipophilicity and bacterial cell penetration. It is a white to cream-colored, odorless, crystalline powder with a bitter taste, sparingly soluble in water but more soluble in organic solvents like methanol.

Mechanism of Action

Trimethoprim exerts its bacteriostatic effect by selectively and competitively inhibiting bacterial dihydrofolate reductase (DHFR). This enzyme is crucial in the folate synthesis pathway, catalyzing the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF). THF is an essential cofactor in the synthesis of thymidine, purines, and several amino acids. By blocking this conversion, trimethoprim depletes the intracellular pool of THF, leading to the cessation of bacterial DNA, RNA, and protein synthesis, and ultimately inhibiting bacterial growth and replication.

A key feature of trimethoprim is its high selectivity for bacterial DHFR, which is structurally distinct from the mammalian enzyme. It binds to bacterial DHFR approximately 50,000 to 100,000 times more efficiently than to the human counterpart. This selective toxicity underpins its utility as an antimicrobial with a relatively favorable safety profile for human use.

Pharmacokinetics

Trimethoprim is well-absorbed from the gastrointestinal tract, with oral bioavailability exceeding 90%. Peak plasma concentrations are typically achieved within 1 to 4 hours post-administration. It demonstrates good tissue penetration, achieving therapeutic concentrations in the kidneys, lungs, prostate, bile, cerebrospinal fluid, and vaginal secretions. Its volume of distribution is relatively high (approximately 1.2–1.8 L/kg), and it is about 42–46% protein-bound. The primary route of elimination is renal, Revisión Basada en Evidencia with about 50-60% of an unchanged drug excreted in the urine within 24 hours. This renal excretion contributes to its high efficacy in treating urinary tract infections (UTIs). Its elimination half-life is approximately 8 to 14 hours in adults with normal renal function, allowing for twice-daily dosing.

Antimicrobial Spectrum and Clinical Applications

Trimethoprim is primarily active against a broad range of Gram-positive and Gram-negative bacteria, though its spectrum is not universal.

• 
  
• Common Susceptible Pathogens: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter spp., Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus (including some MRSA strains when used in combination), and Pneumocystis jirovecii (a fungus, targeted by the TMP-SMX combination).
  
• Notable Intrinsic Resistance: Pseudomonas aeruginosa, Bacteroides fragilis, and Mycobacterium tuberculosis are inherently resistant.
  

Primary Clinical Uses:

1. 
   
2. Uncomplicated Urinary Tract Infections (UTIs): Trimethoprim alone is a first-line agent for acute, uncomplicated cystitis, especially in regions with low resistance rates.
   
3. Respiratory Tract Infections: Used for acute exacerbations of chronic bronchitis and otitis media, often in the TMP-SMX combination.
   
4. Co-trimoxazole (TMP-SMX): This combination is critical for treating and preventing Pneumocystis jirovecii pneumonia (PCP) in immunocompromised patients (e.g., those with HIV/AIDS). It is also used for nocardiosis, toxoplasmosis prophylaxis, and infections caused by Stenotrophomonas maltophilia.
   
5. Gastrointestinal Infections: Used for traveler's diarrhea caused by enterotoxigenic E. coli and in the management of shigellosis.
   

Adverse Effects and Contraindications

Trimethoprim is generally well-tolerated, but several adverse effects are noteworthy:

• 
  
• Hematological Effects: The most significant concern is dose-related interference with folate metabolism in sensitive individuals, potentially leading to megaloblastic anemia, leukopenia, and thrombocytopenia. This risk is higher in patients with pre-existing folate deficiency, the elderly, or those with renal impairment.
  
• Hyperkalemia: Trimethoprim has a structural similarity to amiloride and can inhibit sodium channels in the distal renal tubule, reducing potassium excretion. This effect is particularly relevant in elderly patients, those on concomitant medications like ACE inhibitors, or individuals with renal insufficiency.
  
• Cutaneous Reactions: Skin rashes, ranging from mild maculopapular eruptions to severe reactions like Stevens-Johnson syndrome (more commonly associated with the sulfamethoxazole component in co-trimoxazole).
  
• Gastrointestinal Disturbances: Nausea, vomiting, and glossitis.
  

Contraindications include documented hypersensitivity to trimethoprim, significant hepatic or renal failure, and patients with megaloblastic anemia due to folate deficiency. Caution is advised during pregnancy (Category C) and lactation.

Antimicrobial Resistance

The widespread use of trimethoprim has led to a steady increase in bacterial resistance, which now poses a significant clinical challenge. Resistance mechanisms include:

1. 
   
2. Chromosomal Mutations: Mutations in the gene encoding the bacterial DHFR enzyme (folA) can reduce the drug's binding affinity.
   
3. Acquisition of Plasmid-Mediated Resistant DHFR Genes: This is the most common and concerning mechanism. Bacteria acquire mobile genetic elements carrying genes for alternative, drug-resistant DHFR enzymes (e.g., dfrA, dfrB families). These genes confer high-level resistance and are readily transferable between bacteria.
   
4. Reduced Drug Permeability: Changes in outer membrane porins in Gram-negative bacteria can decrease intracellular drug accumulation.
   
5. Overproduction of DHFR: Gene amplification leading to enzyme overproduction can overwhelm the inhibitory capacity of trimethoprim.
   

Resistance rates in E. coli causing community-acquired UTIs exceed 20% in many parts of the world, guiding the need for local antibiogram-based empirical therapy.

Conclusion and Future Perspectives

Trimethoprim remains a valuable, cost-effective oral antibacterial agent over five decades after its introduction. Its role in treating UTIs, its synergistic power in co-trimoxazole, and its life-saving application in PCP prophylaxis are undeniable. However, its future utility is constrained by the relentless rise of antimicrobial resistance, driven by the horizontal transfer of resistant genes. Prudent use, guided by antimicrobial stewardship principles and local resistance patterns, is essential to preserve its efficacy. Ongoing research explores novel DHFR inhibitors and combination therapies to overcome resistance. Furthermore, investigations into the non-antibiotic effects of trimethoprim, such as potential anti-inflammatory properties, may open new therapeutic avenues. In summary, trimethoprim is a classic example of a targeted antimicrobial whose continued clinical relevance depends on a balanced approach between application and conservation.